TY - JOUR
T1 - Rapid recurrence of Helicobacter pylori infection in Peruvian patients after successful eradication
AU - Ramirez-Ramos, Alberto
AU - Gilman, Robert H.
AU - Leon-Barua, Raul
AU - Recavarren-Arce, Sixto
AU - Watanabe, Jose
AU - Salazar, Guillermo
AU - Checkley, William
AU - McDonald, Jeff
AU - Valdez, Yanet
AU - Cordero, Luis
AU - Carrazco, Juan
AU - Berendson, Robert
AU - Vasquez, Alicia
AU - Rodriguez, Carlos
AU - Miyagi, Juan
AU - Bonilla, Jose
AU - Alvarez, Maritza
AU - Gutierrez, Vilma
N1 - Funding Information:
This study was funded in part by the National Institutes of Health (grant DK 39048) and the RG-ER fund. * Other members include Robert Berendson, Yanet Valdez, Alicia Vasquez, Carlos Rodriguez, Juan Miyagi, Jose Bonilla, Maritza Alvarez, and Vilma Gutierrez.
PY - 1997
Y1 - 1997
N2 - Helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer. Since gastric cancer is common in Peru, eradication of H. pylori may help to reduce the occurrence of gastric cancer. This study involved three randomized trials to determine the efficacy of four different triple-drug therapy regimens. The most successful regimen was furazolidone combined with bismuth subsalicylate and amoxicillin, which eradicated infection in 82% of patients. Patients successfully treated were followed every 2-3 months to determine the recurrence rate of H. pylori infection. Of 105 patients with H. pylori eradication documented by pathology and culture, 52% (55) returned for follow-up endoscopy, and in 73% (40) of these 55 the infection recurred during the 8-month follow-up period. Thirty-five patients from whom H. pylori was eradicated and who were tested for antibodies to H. pylori remained consistently seropositive. Rapid recurrence of H. pylori infection after successful eradication suggests that measures other than antimicrobial therapy are needed to fight H. pylori in developing countries.
AB - Helicobacter pylori is associated with gastritis, peptic ulcer disease, and gastric cancer. Since gastric cancer is common in Peru, eradication of H. pylori may help to reduce the occurrence of gastric cancer. This study involved three randomized trials to determine the efficacy of four different triple-drug therapy regimens. The most successful regimen was furazolidone combined with bismuth subsalicylate and amoxicillin, which eradicated infection in 82% of patients. Patients successfully treated were followed every 2-3 months to determine the recurrence rate of H. pylori infection. Of 105 patients with H. pylori eradication documented by pathology and culture, 52% (55) returned for follow-up endoscopy, and in 73% (40) of these 55 the infection recurred during the 8-month follow-up period. Thirty-five patients from whom H. pylori was eradicated and who were tested for antibodies to H. pylori remained consistently seropositive. Rapid recurrence of H. pylori infection after successful eradication suggests that measures other than antimicrobial therapy are needed to fight H. pylori in developing countries.
UR - http://www.scopus.com/inward/record.url?scp=20644462799&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=20644462799&partnerID=8YFLogxK
U2 - 10.1086/516083
DO - 10.1086/516083
M3 - Article
C2 - 9402351
AN - SCOPUS:20644462799
SN - 1058-4838
VL - 25
SP - 1027
EP - 1031
JO - Clinical Infectious Diseases
JF - Clinical Infectious Diseases
IS - 5
ER -